Lgt Capital Partners Ltd. Autolus Therapeutics PLC Transaction History

Lgt Capital Partners Ltd.

  • $2.81 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 12, 2024
SELL
$3.33 - $5.68 $599,400 - $1.02 Million
-180,000 Reduced 32.73%
370,000 $1.29 Million
Q2 2022

Jul 13, 2022
BUY
$2.04 - $4.68 $102,000 - $234,000
50,000 Added 10.0%
550,000 $1.56 Million
Q1 2022

Apr 13, 2022
BUY
$3.52 - $5.46 $1.76 Million - $2.73 Million
500,000 New
500,000 $2.09 Million

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Lgt Capital Partners Ltd. Portfolio

Follow Lgt Capital Partners Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lgt Capital Partners Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Lgt Capital Partners Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email